Nexavar - Newsfeeds

Bayer says UK cost agency delays ruling on Nexavar: In a preliminary recommendation in May, NICE said Nexavar, scientifically known as sorafenib, should not be given on the state health service to patients with hepatocellular carcinoma, the most common form of liver cancer. A spokeswoman for Bayer's ...
Unusual 11 Mid-Day Movers 7/22: MEG, SOMX, ONXX, OREX Higher; HEB, ATI ...: The study evaluated Nexavar(R) (sorafenib) tablets in combination with the oral chemotherapeutic, capecitabine, in patients with locally advanced or metastatic HER-2 negative breast cancer. Click here to see the full report. Orexigen Therapeutics, Inc ...
Efficacy of sorafenib on metastatic renal cell carcinoma in Asian ...: The effects of sorafenib in the treatment of advanced renal cell carcinoma (RCC) have been confirmed in an international collaborative phase III trial. This study aims to confirm similar efficacy and treatment-induced toxicities of sorafenib in the ...
Novel Therapeutics for Melanoma: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407,597-612 (2006). Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 ...
Do doctor-politicians have an advantage in the health care debate?: The rejected drugs - bevacizumab (Avastin), sorafenib (Nexavar) and temsirolimus (Torisel) - have similar costs and are used in other countries. Nicole Farmer, of Bayer Schering Pharma Oncology, which makes Nexavar, said: 'This shows why the UK sits ...
Older cancer patients have more frailty than other seniors: Older renal cancer patients appear to benefit from sorafenib treatment Oct 07, 2008 | not rated yet | 0 Older and younger patients with renal cancer derive similar benefit from sorafenib therapy and tolerate the drug ...
Investigating Role Of Brain Tumors In Deafness: He said: "We have already achieved some success in re-profiling an existing drug called sorafenib by using the human in-cell model. The re-profiled drug has a positive affect on multiple brain tumours. As a consequence, we can go straight to clinical ...
Afinitor® Approved In EU As First Treatment Proven To Benefit ...: Eisen, et. al. Sorafenib for Older Patients with Renal Cell Carcinoma. Journal of the Natational Cancer Institute. 2008;100(20):1454-1463. 12. Ferlay, J. et al. Estimates of the cancer incidence and mortality in Europe in 2006. Annals of Oncology.18(3 ...
Afinitor Approved for Advanced Kidney Cancer: Approval was granted for use in people with advanced renal cell cancer who have tried other kinase inhibitors, including Sutent (sunitinib) or Nexavar (sorafenib). A clinical trial evaluating Afinitor's safety and effectiveness was halted early after ...
Potential Can't Buy Me Love: For instance, Nexavar was recently shown to lengthen the time it takes for breast tumors to start growing again when used in combination with Roche's Xeloda. Assuming that result holds up in a phase 3 trial, I see a potential to double Nexavar's ...

Onyx 2Q profit doubles on Nexavar sales: EMERYVILLE, Calif. -- Onyx Pharmaceuticals Inc. said late Tuesday second-quarter profit doubled on higher sales of the cancer drug Nexavar. The company earned $9.4 million, or 16 cents per share, up from profit of $4.5 million, or 8 cents per share ...
The Wrong Way to Invest in the Right Stocks: For instance, Onyx Pharmaceuticals jumped more than 400% in 2007 by expanding the use of its cancer drug, Nexavar, from kidney cancer into liver cancer. Positive clinical trials and FDA approvals bring big rewards for investors -- which is why it's ...
Onyx offering $322 million in stock, notes: Onyx's lead product Nexavar is approved in the U.S. as a treatment for liver cancer and advanced kidney cancer. Bayer HealthCare sells the drug and pays royalties to Onyx. Nexavar is also being developed as a potential treatment for breast and lung ...
Virginia Reclaims #1 Spot: Sales of cancer drug Nexavar rose 161% to 60 million euros. Bayer said operating profit before special items at its CropScience unit, which competes with Syngenta and Monsanto, rose 14% to 262 million euros thanks to its crop-protection unit and cost ...
PHARMA'S MARKET VIDEO: Insight on the pharma company's 11% slide in shares and and outlook, with Bill Weldon, Johnson & Johnson chairman/CEO and CNBC's Mike Huckman. Almost exactly one year since Onyx Pharmaceuticals announced positive results of its drug Nexavar for liver ...
FDA OKs New Kidney Cancer Drug: The FDA approved Afinitor for advanced renal cell carcinoma patients who have already tried another kinase inhibitor -- Sutent or Nexavar. The FDA based its decision on a clinical trial that was discontinued when interim results showed that the growth ...
Scientists Learn How Cancer Drugs Cause Hypertension: ... Aug. 5 (HealthDay News) -- A new study reveals why high blood pressure develops in up to one-third of cancer patients who take drugs to block the formation of blood vessels that feed tumors. " Anti-angiogenesis drugs like Avastin, Sutent or Nexavar ...
Cancer lottery: London patients get three times more funding than ...: Research on patients treated by University Hospitals Birmingham Foundation Trust compared the fate of 40 given the drugs Sutent and Nexavar for kidney cancer with 40 whose requests for funding were denied. Those given the drugs survived 22 ...
Onyx Pharma slides after analyst lowers rating: Onyx also said sales of Nexavar would probably not reach the high end of its annual guidance. The stockis down about 12 percent from Tuesday's closing price. ___ August 10, 2009 01:46 PM EDT Copyright 2009, The Associated Press. All rights reserved ...

Looking for a District of Columbia Nexavar attorney? Get in touch with one of our District of Columbia Nexavar attorneys now.

Content provided by MSN. LegalView is not responsible for the accuracy of the information provided above.

Pages: Previous 1 2 3

Need A Nexavar Attorney?

First Name Last Name Email Address State

Legal Issue

DrugWatch: Nexavar Click to select a Legal Issue

Has Your Health Been Negatively Affected?

Please Describe the Injury

close this window

Nexavar Information

Click to View Our Legal Resources

Looking for a District of Columbia Nexavar attorney? Get in touch with one of our District of Columbia Nexavar attorneys now.

LegalView.info is sponsored by law firms with offices in many states. This website contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Your access to this site does not constitute a legal attorney-client relationship. The choice of a lawyer is an important decision and should not be based solely upon advertisements. To access important information concerning the sponsors and their commitment to the ethical practice of law, click here.

The participating law firms are as follows: Anapol Schwartz (Philadelphia, Pennsylvania; Cherry Hill, New Jersey; Media, Pennsylvania; Reading, Pennsylvania; Wheeling, WV). Cohen, Placitella & Roth (Red Bank, New Jersey; Philadelphia, Pennsylvania). J. F. Humphreys (Charleston, West Virginia). Lopez McHugh (Newport Beach, California; Philadelphia, PA; and Moorestown, NJ). Click here for more information about these law firms.

Some of our partner firms do not accept some types of cases. For details on these case exceptions, click here.

20120517-171350

Close (x)

Looking for an Attorney?

Please type your question:

First Name:
Last Name:
E-mail:
Phone Number *
() -

State * Legal Issue *

DrugWatch: Nexavar Click to select a Legal Issue

Close (x)

Find Legal Help for Your Nexavar Case - Submit Your Information Below

Do you need legal assistance with your Nexavar case?
LegalView may be able to help.

Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *

Last name *

Email Address *

Phone Number *
() -

State *

Legal Issue * DrugWatch: Nexavar Change

Was There an Injury?

Please Describe The Injury

Please State Your Question *

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.

This form is secure and encrypted. More information about secure forms and your privacy here.